ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 257.76

Change

+3.02 (+1.19)%

Market Cap

USD 3.92B

Volume

0.93M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-6.88 (-1.37%)

USD 126.85B
REGN Regeneron Pharmaceuticals Inc

+1.39 (+0.13%)

USD 117.19B
MRNA Moderna Inc

+0.38 (+0.32%)

USD 46.95B
ARGX argenx NV ADR

+6.66 (+1.31%)

USD 30.45B
BGNE BeiGene Ltd

+9.60 (+6.12%)

USD 16.93B
RPRX Royalty Pharma Plc

-0.37 (-1.30%)

USD 16.81B
BMRN Biomarin Pharmaceutical Inc

-0.06 (-0.07%)

USD 15.97B
UTHR United Therapeutics Corporatio..

-24.25 (-7.18%)

USD 14.60B
SRPT Sarepta Therapeutics Inc

-0.80 (-0.56%)

USD 13.76B
INCY Incyte Corporation

-2.72 (-4.01%)

USD 12.98B

ETFs Containing ALNY

EUSA iShares MSCI USA Equal We.. 1,000.00 % 0.15 %

+0.56 (+0.82%)

USD 0.79B
SDG iShares MSCI Global Impac.. 1,000.00 % 0.49 %

+1.01 (+0.82%)

USD 0.24B
MSGR 6.64 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 6.44 % 0.00 %

+0.04 (+0.82%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.44 % 0.00 %

-0.07 (0.82%)

USD 5.83M
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

+0.18 (+0.82%)

N/A
GNOG:LSE Global X Genomics & Biote.. 5.68 % 0.00 %

+0.05 (+0.82%)

USD 6.19M
CURG:LSE VanEck Genomics and Healt.. 5.53 % 0.00 %

+0.13 (+0.82%)

USD 7.04M
BTEC Principal Healthcare Inno.. 4.66 % 0.42 %

+0.40 (+0.82%)

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.89 % 0.00 %

+0.07 (+0.82%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

+0.04 (+0.82%)

N/A
2B70:F iShares NASDAQ US Biotech.. 3.20 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

-0.03 (0.82%)

N/A
CURE:AU ETFS S&P Biotech ETF 2.92 % 0.00 %

+0.16 (+0.82%)

USD 0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 2.87 % 0.00 %

+0.03 (+0.82%)

USD 0.52B
BBP Virtus LifeSci Biotech Pr.. 2.19 % 0.79 %

-0.03 (0.82%)

USD 0.02B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

+0.22 (+0.82%)

N/A
EQJS:LSE Invesco NASDAQ Next Gener.. 2.12 % 0.00 %

+18.00 (+0.82%)

USD 0.04B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

+0.17 (+0.82%)

USD 0.05B
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
FXH First Trust Health Care A.. 2.11 % 0.63 %

-0.32 (0.82%)

USD 1.26B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

+0.26 (+0.82%)

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.88 % 0.95 %

-0.24 (0.82%)

USD 0.09B
TMFX Motley Fool Next Index ET.. 1.76 % 0.00 %

+0.08 (+0.82%)

USD 0.02B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

+3.55 (+0.82%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

+0.13 (+0.82%)

N/A
ETHO Etho Climate Leadership U.. 0.53 % 0.45 %

+0.48 (+0.82%)

USD 0.18B
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.50 % 0.00 %

+0.07 (+0.82%)

USD 0.19B
IUSZ:SW iShares Edge MSCI USA Siz.. 0.50 % 0.00 %

+0.09 (+0.82%)

N/A
IUSF:LSE iShares IV Public Limited.. 0.48 % 0.00 %

+7.38 (+0.82%)

USD 0.22B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.48 % 0.00 %

+0.09 (+0.82%)

USD 0.22B
IS3T:XETRA iShares MSCI World Size F.. 0.21 % 0.00 %

+0.48 (+0.82%)

USD 0.24B
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.26B
IWFS:LSE iShares MSCI World Size F.. 0.20 % 0.00 %

+37.50 (+0.82%)

USD 0.25B
IWSZ:LSE iShares IV Public Limited.. 0.20 % 0.00 %

+0.58 (+0.82%)

USD 0.25B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

+0.03 (+0.82%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.09 (+0.82%)

USD 7.71B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.06 (+0.82%)

USD 0.09B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+0.82%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.82%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+8.45 (+0.82%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.82%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.07 (+0.82%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.05 (+0.82%)

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.54 (+0.82%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM ETFMG Treatments Testing .. 0.00 % 0.00 %

+0.09 (+0.82%)

USD 0.01B
BMED BlackRock Future Health E.. 0.00 % 0.00 %

+0.09 (+0.82%)

USD 4.21M
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

+0.27 (+0.82%)

USD 0.66B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

+0.30 (+0.82%)

USD 0.03B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.02 (+0.82%)

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.38 (+0.82%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.66% 80% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.66% 80% B- 88% B+
Trailing 12 Months  
Capital Gain 27.67% 79% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.67% 79% B- 83% B
Trailing 5 Years  
Capital Gain 260.30% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 260.30% 92% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 16.57% 72% C 76% C+
Dividend Return 16.57% 72% C 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.99% 83% B 59% D-
Risk Adjusted Return 53.47% 94% A 81% B-
Market Capitalization 3.92B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 309.37 0% 1%
Price/Free Cash Flow Ratio -81.96 99% 97%
Management Effectiveness  
Return on Equity -1,500.66% 5% 2%
Return on Invested Capital -34.83% 70% 28%
Return on Assets -3.05% 94% 45%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.